A March 18 study published by Cao et al. in the New England Journal of Medicine showed that “In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care.“
Graph from Cao et al. 2020 showing that there is no statistically significant difference between patients treated with lopinavir/ritonavir and those not treated in the time course of how quickly they experience clinical improvement.
Graph from Cao et al. 2020 showing that there is no statistically significant different in the time course of viral load reduction between patients treated with lopinavir/ritonavir and those not treated.